PubMed COVID-19 Clinical Care

Acute lung injury (ALI) is one of the most common complications in COVID-19 and also a syndrome of acute respiratory failure with high mortality rates, but lacks effective therapeutic drugs. Natural products provide inspiration and have proven to be

CONCLUSIONS: Long-term immunosuppressive therapy may be preferred in proper cases of post-COVID-19-ILD as an effective and safe treatment option that improves the quality of life, respiratory parameters, and radiologic findings.

This study aims to identify the type of support received by family caregivers of older people during the COVID-19 pandemic, as well as the associated socioeconomic health and care-related factors. Data from CUIDA-COVID study, an online questionnaire

CONCLUSIONS: New-onset T1D and DKA in children are more often diagnosed during weekdays than weekends and holidays.

CONCLUSION: The rate of extended hospitalization and COVID-19-specific death in cancer patients was notably high and could be influenced by comorbidities, cancer treatment status, and clinical fragility. These observations may aid in developing risk

The flu season is caused by a combination of different pathogens, including influenza viruses (IVS), that cause the flu, and non-influenza respiratory viruses (NIRVs), that cause common colds or influenza-like illness. These viruses exhibit similar

Early treatment with a first-line therapy (nirmatrelvir/ritonavir [Paxlovid] or remdesivir) or second-line therapy (molnupiravir) prevents hospitalization and death among patients with mild-to-moderate COVID-19 who are at risk for severe disease and

A randomized survey experiment (N = 2,868) was conducted at the onset of the COVID-19 pandemic to examine the effects of information provision on individuals' cooperation with stay-home activities. Employing a 2 × 2 factorial design, the study

This paper describes developments in the fields of asthma and COPD self-management interventions (SMIs) over the last two decades and discusses future directions. Evidence around SMIs has exponentially grown. Efficacy on group level is convincing and

INTRODUCTION: First-time pass rates of the North American Pharmacist Licensure Examination (NAPLEX) have declined 7% from 2019 to 2022 with more than a third of schools experiencing a decline of ≥10%.